District of Columbia — drug testing employment law

At a glance: District of Columbia

Overview: drug testing in District of Columbia

The District of Columbia legalized cannabis possession and home cultivation in 2014 (Initiative 71), though commercial recreational sales remain restricted by the federal Harris Rider that bars D.C. from spending appropriated funds to regulate commercial sales. In 2022, the Council passed the Cannabis Employment Protections Amendment Act (D.C. Code § 32-931 et seq.), which provides robust employment protections for off-duty cannabis use.

Cannabis law and workplace testing

The Cannabis Employment Protections Amendment Act prohibits D.C. employers from refusing to hire, terminating, suspending, or otherwise penalizing an employee for use of cannabis, being a qualifying patient, or failing a cannabis drug test, unless the position is designated safety-sensitive or the employee was impaired during work hours. The Act includes specific notice and definition requirements for safety-sensitive positions.

Specific testing rules in District of Columbia

The table below summarizes how District of Columbia typically treats four common workplace testing scenarios. Each row reflects the dominant statutory or case-law position; carve-outs (federal-contractor, DOT-regulated, safety-sensitive, etc.) may shift any individual analysis.

Federal overlay: DOT and federal contractors

In all U.S. states — including District of Columbia — DOT-regulated employees (safety-sensitive roles in transportation industries under 49 CFR Part 40) and federal-contractor employees subject to the federal Drug-Free Workplace Act of 1988 are testable under federal rules regardless of state cannabis status or workplace-testing restrictions. State law cannot reduce federal testing obligations for these populations. Where state law otherwise restricts cannabis testing, the federal-overlay carve-out typically preserves the employer's authority for these federally affected roles.

For employers in District of Columbia

D.C. employers must carefully designate safety-sensitive positions in writing per the Act's definitions. For non-safety-sensitive positions, cannabis-positive tests alone are insufficient grounds for adverse action. DOT and federal-contractor carve-outs apply.

• Written policy. Document the substances tested, the cutoff levels, the testing modalities (urine / oral fluid / hair), and the consequences of a non-negative result.
• Notice. Provide written notice before testing begins and obtain signed acknowledgement where the state requires it.
• Certified laboratory. Use a SAMHSA-certified or equivalent laboratory; document chain of custody.
• Confirmation testing. Confirm any non-negative initial result with mass-spectrometry (GC-MS or LC-MS/MS) before any adverse action.
• MRO review. Engage a qualified Medical Review Officer to review all non-negative results before reporting to the employer.
• Safety-sensitive designations. If the role is statutorily exempt as safety-sensitive, document the designation in writing using the state\'s statutory definition.
• Medical cannabis disclosures. Where state law provides patient protection, engage an interactive accommodation process before adverse action.

For workers in District of Columbia

D.C. workers in non-safety-sensitive positions are broadly protected from cannabis-based employment discrimination. Confirm whether your position is designated safety-sensitive — the designation must follow statutory criteria and be communicated to you.

• Know the policy. Request a copy of your employer\'s written testing policy — it should specify when testing occurs, what is tested, and how to challenge a result.
• Disclose medications to the MRO, not the employer. The Medical Review Officer reviews non-negative results before they are reported and can resolve a legitimate prescription explanation.
• Document medical cannabis status. If you are a registered medical cannabis patient in a state with patient protection, document your status with HR before testing.
• Confirmation testing. Any non-negative initial result should be confirmed by GC-MS or LC-MS/MS before adverse action.
• Appeal rights. Many state statutes provide an appeals process — read your employer\'s policy carefully.

Key statutes and citations

The following statutory citations are the primary controlling authority for drug testing employment law in District of Columbia. We provide citations only — confirm current text via your state legislature\'s codified statutes (or an authoritative legal research platform) before relying on this information.

• Cannabis Employment Protections Amendment Act of 2022 — D.C. Code § 32-931 et seq.
• Legalization of Marijuana for Medical Treatment Initiative — D.C. Code § 7-1671.01 et seq.

Multi-state employers operating in District of Columbia

A national or multi-state employer\'s policy that works in a permissive state (e.g., Alabama or Texas) may not be lawful as applied to employees in District of Columbia, and vice versa. Common multi-state pitfalls include: applying a national pre-employment cannabis screen in jurisdictions that prohibit it; treating a positive cannabis test as automatic disqualification where state law restricts that outcome; failing to designate safety-sensitive roles in compliance with the relevant state\'s statutory definition; and not maintaining state-specific written policies and acknowledgements. For multi-state programs, see our multi-state employer guide.

How this page is built and reviewed

This page combines a structured data layer (cannabis status, statutory protection levels, voluntary program details, statute citations) with state-specific narrative drafted from primary statutes and authoritative secondary sources. Every claim should trace either to a statute citation, an authoritative secondary source (e.g., NCSL, EEOC, DOT, SHRM, ASAM), or general background knowledge clearly framed as such. The page is reviewed against the listed sources on each material amendment.

Found something out of date? Let us know — we update state pages as statutes and case law evolve.